Regeneron Pharmaceuticals Receives Average Rating of “Buy” from Analysts (NASDAQ:REGN)
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) have been given an average rating of “Buy” by the twenty-two analysts that are presently covering the stock, Analyst Ratings Net reports. Five equities research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $345.94.
REGN has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.03% on Tuesday, hitting $338.70. The stock had a trading volume of 31,767 shares. Regeneron Pharmaceuticals has a 1-year low of $227.64 and a 1-year high of $352.49. The stock’s 50-day moving average is $309.0 and its 200-day moving average is $306.9. The company has a market cap of $34.002 billion and a P/E ratio of 96.42.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.08 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, SVP Neil Stahl unloaded 11,646 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $339.96, for a total value of $3,959,174.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.